Rational Design of Amyloid Beta-Protein Aggregation and Toxicity Inhibitors

About the Research Project
Program
Award Type
Pilot
Award Amount
$100,000
Active Dates
April 01, 2008 - March 31, 2010
Grant ID
A2008350
Goals
In this project we will use a novel approach that combines our most current understanding of the molecular processes that lead to AD. We do that by “tailoring” sophisticated weapons that target what is believed to be the very first event along the pathway that leads to formation of the toxic molecules that rob AD patients of their memory and personality.
Summary
Alzheimer’s disease (AD) is a current major public health threat, which despite tremendous research efforts, to date has no cure. To cure and prevent the disease we must invent drugs that treat the root of the problem. In this project we will use a novel approach that combines our most current understanding of the molecular processes that lead to AD. We do that by “tailoring” sophisticated weapons that target what is believed to be the very first event along the pathway that leads to formation of the toxic molecules that rob AD patients of their memory and personality. Unlike the direction used by most pharmaceutical companies – screening of large, random collections of molecules,our study is the first example of using a rational-design approach that is based on the three-dimensional structure of the toxic protein that causes AD.
Related Grants
Alzheimer's Disease Research
Personalized Proteomics to Understand and Predict Alzheimer’s Progression
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
Federica Anastasi, PhD
Current Organization
Barcelonaβeta Brain Research Center
Alzheimer's Disease Research
Neuroimaging and Neuropathology of Alzheimer’s Disease in Down Syndrome
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
Jr-Jiun Liou, PhD
Current Organization
University of Pittsburgh
Alzheimer's Disease Research
Neurostimulation to Improve Depression and Memory in Dementia
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Davide Cappon, PhD
Current Organization
Hebrew Rehabilitation Center